Nkarta, INC. (NKTX) — SEC Filings

Overview

Nkarta, INC. (NKTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 6, 2026: Nkarta, Inc. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing relates to Act 33 and has the file number 333-294611. The company's mailing and business address is 1150 Veterans Boulevard, South San Francisco, CA 94080.

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Nkarta, INC. is neutral.

Filing Type Overview

Nkarta, INC. (NKTX) has filed 1 EFFECT, 1 S-3, 9 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 7 SC 13G/A, 1 8-K/A, 4 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• Nkarta, Inc. Registration Statement Declared Effective — EFFECT · Apr 6, 2026 Risk: medium
  Nkarta, Inc. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing relates to Act 33 and has the file numb
• Nkarta Files S-3: Prepares for Future Capital Raises — S-3 · Mar 25, 2026
  Nkarta, Inc. filed an S-3 registration statement on March 25, 2026, allowing them to potentially sell new securities in the future. This filing, under CIK 00017
• Nkarta Files 8-K on Financial Results, Operations — 8-K · Mar 25, 2026
  Nkarta, Inc. filed an 8-K on March 25, 2026, reporting its results of operations and financial condition under Item 2.02. This filing includes an exhibit EX-99.
• Nkarta Narrows Q3 Loss Amid R&D Spend Cuts, Cash Position Improves — 10-Q · Nov 10, 2025 Risk: high
  Nkarta, Inc. reported a net loss of $21.7 million for the three months ended September 30, 2025, an improvement from a net loss of $28.3 million in the same per
• Nkarta, Inc. Files 8-K on Operations and Financials — 8-K · Aug 12, 2025 Risk: low
  Nkarta, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• Nkarta, Inc. Files 8-K: Director Changes, Officer Appointments, and More — 8-K · Jun 6, 2025 Risk: medium
  On June 3, 2025, Nkarta, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, changes in certain officer
• Nkarta, Inc. Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Nkarta, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Ke
• Nkarta, Inc. Files Definitive Proxy Statement for June 5 Meeting — DEF 14A · Apr 21, 2025 Risk: low
  Nkarta, Inc. filed its definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 5, 2025. The filing concerns the solicitation of p
• Nkarta, Inc. Files 2024 10-K Annual Report — 10-K · Mar 26, 2025 Risk: medium
  Nkarta, Inc. filed its 2024 10-K on March 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations,
• SC 13G Filing — SC 13G · Dec 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Nkarta, Inc. Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Nkarta, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 2024. Fina
• SC 13G/A Filing — SC 13G/A · Oct 25, 2024
• SC 13G Filing — SC 13G · Oct 24, 2024
• Nkarta, Inc. Amends Prior 8-K Filing — 8-K/A · Aug 16, 2024 Risk: medium
  Nkarta, Inc. filed an 8-K/A on August 16, 2024, to amend a previous filing related to its results of operations and financial condition. The amendment specifica
• Nkarta Reports Q2 Financials, Cash Down to $236.3M — 10-Q · Aug 13, 2024 Risk: medium
  Nkarta, Inc. filed its 10-Q for the period ending June 30, 2024, reporting its financial results. The company's cash and cash equivalents, restricted cash, and
• Nkarta Appoints New CMO, Adds Director — 8-K · Jul 16, 2024 Risk: medium
  On July 10, 2024, Nkarta, Inc. announced the appointment of Dr. James M. Robinson as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Boar
• Nkarta, Inc. Files 8-K Report — 8-K · Jun 27, 2024 Risk: low
  On June 27, 2024, Nkarta, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD
• Nkarta, Inc. Holds Annual Meeting, Ratifies Auditors — 8-K · Jun 13, 2024 Risk: low
  On June 13, 2024, Nkarta, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders, where
• Nkarta, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Nkarta, Inc. (NKTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Nkarta, Inc. reported financial results for the quarter ended March 31, 2024. T
• Nkarta, Inc. files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 25, 2024 Risk: low
  Nkarta, Inc. (NKTX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Annual meeting scheduled for June 13, 2024, at 9:00 a.m. Pacific Time, hel
• SC 13G/A Filing — SC 13G/A · Apr 5, 2024
• Samsara BioCapital Amends Nkarta Stake Filing — SC 13D/A · Mar 29, 2024 Risk: medium
  Samsara BioCapital, L.P. and Samsara BioCapital GP, LLC, through their group member Srinivas Akkareju, have amended their Schedule 13D filing regarding Nkarta,
• NEA 15 Amends Nkarta Stake — SC 13D/A · Mar 28, 2024 Risk: medium
  On March 28, 2024, New Enterprise Associates 15, L.P. (NEA 15) filed an amendment to its Schedule 13D, disclosing a change in its beneficial ownership of Nkarta
• GSK plc Amends Nkarta, Inc. Filing — SC 13D/A · Mar 28, 2024 Risk: medium
  GSK plc, formerly GlaxoSmithKline, has amended its SC 13D filing for Nkarta, Inc. on March 28, 2024. The filing indicates a change in beneficial ownership, with
• Nkarta, Inc. Files 8-K — 8-K · Mar 28, 2024 Risk: low
  Nkarta, Inc. filed an 8-K on March 28, 2024, reporting an event that occurred on March 25, 2024. The filing is categorized under 'Other Events' and 'Financial S
• Nkarta, Inc. Files 8-K Report — 8-K · Mar 25, 2024 Risk: low
  On March 25, 2024, Nkarta, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure and
• Nkarta, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: medium
  Nkarta, Inc. (NKTX) filed a Annual Report (10-K) with the SEC on March 21, 2024. Nkarta, Inc. filed its 2023 Form 10-K on March 21, 2024. The filing covers the
• LSP 6 Holding C.V. Amends Nkarta Stake on Feb 8 — SC 13D/A · Feb 9, 2024 Risk: medium
  LSP 6 Holding C.V. filed an amendment to their Schedule 13D on February 8, 2024, indicating a change in their beneficial ownership of Nkarta, Inc. common stock.
• Adage Capital Partners Cuts Nkarta Stake to 7.0% — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, disclosing its ownership in Nkarta, Inc. As of December 31, 2023, Adage Capital Part
• BlackRock Amends Nkarta Stake, Signals Continued Passive Investment — SC 13G/A · Jan 31, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 31, 2024, disclosing its ownership of Nkarta, Inc. common stock as of December 31, 2023. This filing indica
• Boxer Capital Group Takes 19.9% Stake in Nkarta, Inc. — SC 13G · Jan 18, 2024
  Boxer Capital, LLC, a Delaware-based investment firm, has reported a significant stake in Nkarta, Inc. (NKTR), a pharmaceutical company, as of January 8, 2024.
• Nkarta 8-K: Emerging Growth Status Confirmed, Reg FD Disclosure — 8-K · Jan 8, 2024
  Nkarta, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. This filin

Risk Profile

Risk Assessment: Of NKTX's 22 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nkarta, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: Not Disclosed
• Net Income: -$21.7M
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: $60.1M
• Operating Margin: Not Disclosed
• Total Assets: $427.2M
• Total Debt: Not Disclosed

Key Executives

• Dr. James M. Robinson
• Ms. Jennifer L. Jones
• Srinivas Akkareju
• Abrar Hussain
• Anthony A. Florence, Jr.
• Forest Baskett
• Mohamad H. Makhzoumi
• Scott D. Sandell
• Stephanie Brecher
• Victoria A. Whyte
• Bas Vaessen

Industry Context

Nkarta operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cell therapy. The development of engineered NK cell therapies is a cutting-edge area with significant potential but also high scientific and clinical risk. The industry is characterized by substantial R&D investment, long development timelines, and a complex regulatory landscape, with numerous companies vying for breakthroughs in oncology and other therapeutic areas.

Top Tags

sec-filing (7) · biotech (7) · financials (4) · 10-Q (4) · amendment (4) · corporate-governance (3) · ownership-change (3) · institutional-ownership (3) · 8-K (2) · Biotechnology (2)

Key Numbers

• Effectiveness Date: 2026-04-03 — The date the registration statement became effective.
• File Number: 333-294611 — The SEC file number for this registration statement.
• Net Loss (Q3 2025): $21.7M — Decreased from $28.3M in Q3 2024, indicating improved financial performance.
• Net Loss (YTD Sep 2025): $76.7M — Decreased from $82.9M in YTD Sep 2024, showing a reduced overall loss.
• Cash and Cash Equivalents (Sep 30, 2025): $60.1M — Increased from $27.9M at Dec 31, 2024, strengthening liquidity.
• Research and Development Expenses (YTD Sep 2025): $65.1M — Decreased from $73.6M in YTD Sep 2024, reflecting cost management.
• Accumulated Deficit (Sep 30, 2025): $620.9M — Indicates significant historical losses and the need for future profitability.
• Common Stock Shares Outstanding (Nov 5, 2025): 71,029,512 — Reflects the current share count for valuation.
• Total Assets (Sep 30, 2025): $427.2M — Decreased from $501.2M at Dec 31, 2024, primarily due to investment changes.
• Reporting Period End Date: 2025-03-31 — The end date for the financial information presented in the 10-Q.
• Filing Date: 2025-05-14 — The date Nkarta, Inc. submitted this 10-Q to the SEC.
• Prior Year End Date: 2024-12-31 — Reference point for comparative financial data from the previous fiscal year.
• Annual Meeting Date: 20250605 — Shareholders will vote on proposals at this date.
• Fiscal Year End: 2024-12-31 — Reporting period for the 10-K
• SIC Code: 2834 — Standard Industrial Classification code for Pharmaceutical Preparations, indicating the company's industry.

Related Companies

NKTR

Frequently Asked Questions